- Home
- Applications
- europe
- for treatment of metastatic bone cancers
Show results for
Refine by
For Treatment Of Metastatic Bone Cancers Product Applications In Europe
11 applications found
4 Ways Digital Can Transform Treatment Selection in Oncology Expert insights on the challenges care teams face in pairing patients with oncology treatments and how digital health solutions can help New and innovative cancer treatments are coming to market faster than ever—a huge win for both patients and care teams. However, with the influx of new treatments also comes an “information avalanche.” Simply put, oncologists are struggling with the sheer volume of information they need to keep ...
ByBrightInsight, Inc based in San Jose, CALIFORNIA (USA)
The development of highly cytotoxic drugs is needed for the success of the treatment in tumor cells. Paradoxically, the high toxicity limits its efficacy and application in vivo, causing damage to non-target organs and severe secondary effects. The use of directed liposomes has allowed the advance of many cancer drugs to preclinical and clinical trials, reducing side effects, and increasing their therapeutic index at the same time. More than 15 cancer liposomed drugs are currently clinically ...
ByNanovex Biotechnologies based in Llanera, SPAIN
PLGA nanospheres have already been successfully used in vitro and in clinical trials. Results show that drugs encapsulated in PLGA nanoparticles have superior accumulation in the tumor environment, reduced tumor size and enhanced inhibition of cell proliferation. This is thanks to increased cell penetration and reduced toxicity of encapsulated compounds. Because of the higher accumulation in tumoral areas PLGA nanoparticles are also useful for cancer diagnosis and imaging which has a key role in clinical oncology ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Providing physicians with innovative and meaningful assays for the earlier detection of clinically significantly prostate ...
ByMDxHealth based in Irvine, CALIFORNIA (USA)
We have developed proprietary methods for expressing immunotherapeutic payloads in a highly controlled and specific manner within tumors. IFN-α is a well-known therapeutic that was previously administered systemically for treatment of various cancers but it is currently rarely used because of its systemic toxicity. In the tumor microenvironment, IFN-α exerts its anti-tumor activity both directly by promoting cancer cell apoptosis and inhibiting vascularization and indirectly by restoring anti-tumor ...
ByGenenta Science based in Milano, ITALY
Like other nanocarriers, synthetic exosomes can be used to treat different types of cancer successfully, by encapsulating the desired anti-tumoral drug or RNA and enzymes. Several studies have used engineered exosomes from dendritic or macrophage cells to release chemotherapeutic compounds as doxorubicin, paclitaxel miRNA or siRNA to induce antitumoral activity. Rodent mammary carcinoma, mice lung cancer, glioma and pancreatic cancer are just some targeted diseases in preclinical testing using exosome delivery ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Dysregulation of immune cell functions can result in many serious and fatal diseases that require re-modulating the immune cells and restoring their normal response. Monitoring of immune cells while interacting with self-cells, pathogens, and cancer promotes our understanding of immune response or its failure ...
ByTelight based in Brno, CZECH REPUBLIC
Gastric cancer is a disease in which cancer cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas, a cancer that begins in glandular tissue. Gastric cancer is often in an advanced stage when it is diagnosed. At this stage, it can often be treated, but rarely ...
ByAscelia Pharma AB based in Malmö, SWEDEN
The increase or decrease of a natural immune response to obtain a therapeutic result is the basis of immunotherapy. It holds great promise for the treatment of autoimmune diseases, cancer, and the prevention of transplant ...
ByNanovex Biotechnologies based in Llanera, SPAIN
The antibody drug discovery process differs from the traditional drug discovery of small molecules as it requires the development of hybridomas and the engineering of antibodies to recognize a specific target protein. The production of recombinant antibodies in cancer treatment as well as the development of neutralizing antibodies for infectious diseases, has allowed antibody discovery platforms to interrogate the immune repertoire and develop novel antibody libraries using flow cytometry analysis and cell ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)
Monoclonal antibodies (mAbs) are used to treat patients in a variety of conditions such as infectious disease, cancer, and autoimmunity. Discovery of therapeutic antibodies is a laborious process, that depends on high-throughput screening of antibody candidates to determine antigen specificity. Immune repertoire analysis provides accurate, sensitive, and rapid detection of antibody sequences in panning rounds or exposured animal models, accelerating the discovery of ...
ByEnpicom B.V. based in s-Hertogenbosch, NETHERLANDS